Form 4: CalciMedica Director Alan Glicklich Granted Over 39,000 Stock Options

CalciMedica, Inc. Director Alan Glicklich was granted a total of 39,166 stock options with exercise prices of $1.53 and $1.65, following stockholder approval of the company's amended equity incentive plan.

Summary

• CalciMedica, Inc. Director Alan Glicklich was granted a total of 39,166 stock options.
• The grants include four separate tranches of Director Stock Options (Right to Buy).
• One tranche for 10,000 shares has an exercise price of $1.53 and vests 1/12th monthly over one year following March 26, 2025.
• Another tranche for 4,166 shares has an exercise price of $1.53 and is immediately exercisable.
• A third tranche for 15,000 shares has an exercise price of $1.53 and vests 1/9th monthly over one year following April 1, 2025.
• The final tranche for 10,000 shares has an exercise price of $1.65 and vests 1/12th monthly over one year following June 24, 2025, with full vesting by the company's 2026 annual meeting.
• All option grants were approved by the Board of Directors on April 23, 2025, and became effective upon stockholder approval of the Amended 2023 Equity Incentive Plan on June 24, 2025.
• The expiration dates for the options are April 22, 2035, for the first three tranches and June 23, 2035, for the fourth tranche.

Sentiment

Score: 5

Explanation: The document is a standard disclosure of an insider transaction (stock option grant) and does not contain information that would significantly alter the company's perceived value or outlook. It is neutral in sentiment.

Positives

• The granting of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term performance.
• The approval of the Amended 2023 Equity Incentive Plan by stockholders indicates support for the company's compensation strategy.

Future Outlook

The document details future vesting schedules for the granted stock options, indicating that shares will vest monthly over a one-year period following specific dates in March, April, and June 2025, with one tranche fully vesting by the 2026 annual meeting.

Industry Context

This filing is a routine disclosure of an insider transaction, specifically the grant of stock options to a director. It does not provide information on broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• The grant of 39,166 stock options to Alan Glicklich, a Director of CalciMedica, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares upon option exercise, but also potential benefit from increased alignment of director incentives with company performance.
• Director (Alan Glicklich): Receives equity incentives, aligning personal financial interests with the company's long-term success.

Next Steps

• Continued vesting of the granted stock options according to their respective schedules.
• The company's 2026 annual meeting of stockholders, by which one tranche of options will be fully vested.

Key Dates

Keywords

CalciMedica, CALC, Stock Options, Director Compensation, SEC Form 4, Equity Incentive Plan, Insider Transaction, Corporate Governance